TCGA-BH-A0DI-01A-21R-A12P-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 30
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.680
- ANGIOGENESIS+0.590
- HEDGEHOG_SIGNALING+0.520
- COAGULATION+0.480
- KRAS_SIGNALING_UP+0.460
- MYOGENESIS+0.450
- APICAL_JUNCTION+0.420
- UV_RESPONSE_DN+0.380
- TNFA_SIGNALING_VIA_NFKB+0.370
- ALLOGRAFT_REJECTION+0.360
Top 10 suppressed
- E2F_TARGETS-0.660
- MYC_TARGETS_V2-0.560
- MYC_TARGETS_V1-0.550
- G2M_CHECKPOINT-0.530
- OXIDATIVE_PHOSPHORYLATION-0.400
- MTORC1_SIGNALING-0.340
- DNA_REPAIR-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.210
- MITOTIC_SPINDLE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0CZ-01A-11R-A034-07 | — | A | 0.954 |
| 2 | GSM6454738 | — | A | 0.954 |
| 3 | TCGA-BH-A0DV-01A-21R-A12P-07 | — | A | 0.951 |
| 4 | TCGA-BH-A208-01A-11R-A157-07 | — | A | 0.945 |
| 5 | cdb7b56c-ddca-4596-bfa2-6823c12837e2 | — | — | 0.941 |
| 6 | SRR8518425 | — | A | 0.939 |
| 7 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.938 |
| 8 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.935 |
| 9 | TCGA-CV-6934-01A-11R-1915-07 | — | — | 0.932 |
| 10 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.680 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.590 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.520 | Inavolisib | — uncovered |
| COAGULATION | 0.480 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.460 | Inavolisib | — uncovered |
| MYOGENESIS | 0.450 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.420 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |